144 related articles for article (PubMed ID: 29057477)
1. The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.
Tsubaki M; Takeda T; Tomonari Y; Mashimo K; Koumoto YI; Hoshida S; Itoh T; Imano M; Satou T; Sakaguchi K; Nishida S
J Cell Physiol; 2018 May; 233(5):4258-4271. PubMed ID: 29057477
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs.
Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Ogawa N; Mashimo K; Fujiwara D; Takeda T; Mukai J; Sakaguchi K; Satou T; Nishida S
Eur J Cancer; 2013 Nov; 49(17):3708-17. PubMed ID: 23932230
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.
Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Imano M; Satou T; Nishida S
Lab Invest; 2019 Jan; 99(1):72-84. PubMed ID: 30353128
[TBL] [Abstract][Full Text] [Related]
5. Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.
Tsubaki M; Mashimo K; Takeda T; Kino T; Fujita A; Itoh T; Imano M; Sakaguchi K; Satou T; Nishida S
Biomed Pharmacother; 2016 Mar; 78():23-29. PubMed ID: 26898421
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
7. Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.
Scotece M; Gómez R; Conde J; Lopez V; Gómez-Reino JJ; Lago F; Smith AB; Gualillo O
Curr Med Chem; 2013; 20(19):2467-75. PubMed ID: 23521677
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway.
Tsubaki M; Kato C; Isono A; Kaneko J; Isozaki M; Satou T; Itoh T; Kidera Y; Tanimori Y; Yanae M; Nishida S
J Cell Biochem; 2010 Dec; 111(6):1661-72. PubMed ID: 21053363
[TBL] [Abstract][Full Text] [Related]
10. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
[TBL] [Abstract][Full Text] [Related]
11. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
12. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
Terpos E; Politou M; Viniou N; Rahemtulla A
Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
[TBL] [Abstract][Full Text] [Related]
13. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
14. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
15. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
16. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
17. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
[TBL] [Abstract][Full Text] [Related]
19. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
20. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA; Baughn LB; Sarver A; Xia T; Deshpande R; Mansoor A; Walsh SA; Sunderland JJ; Dolloff NG; Linden MA; Zhan F; Janz S; Myers CL; Van Ness BG
Mol Cancer Ther; 2013 Jun; 12(6):1140-50. PubMed ID: 23536725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
